Italian researchers report that 72% of their trial participants being treated for psoriatic arthritis achieved sustained remission with ETN 25 mg biweekly, which was maintained a year after treatment initiation.
Recent evidence has shown that increasing intervals between etanercept (ETN) administration could effectively manage remission with a stable dose in patients with psoriatic arthritis (PsA) who had achieved remission with 25 mg ETN biweekly. Now, Italian researchers report that 72% of their trial participants being treated for PsA achieved sustained remission with ETN 25 mg biweekly, which was maintained a year after treatment initiation.
They note that remission was maintained in their open-label study in 54 patients diagnosed with PsA despite a progressive dose-reduction strategy that was created by increasing the dosing interval (21% with a weekly regimen and 51% with an every-other-week regimen). The findings were published in the Journal of Clinical Rheumatology by Renato de Stefano, MD, and colleagues.
All patients in the study had confirmed, active PsA, despite conventional treatment (synthetic disease-modifying antirheumatic drugs [DMARDs], nonsteroidal anti-inflammatory drugs, and corticosteroids], disease duration of more than 1 year, and were between 18 and 65 years old. They were recruited between September 2012 and June 2015 and followed for 1 year; participants were evaluated at baseline, 3 months, and every 1 month thereafter. The primary study endpoint was the proportion of patients in sustained clinical remission at week 48 with weekly ETN 25-mg therapy and with every-other-week ETN 25-mg therapy.
At the end of the study period, 27 patients (93%) remained in remission: 6 (21%) with a biweekly regimen, 6 (21%) with a weekly regimen, and 15 (51%) with an every-other-week regimen. More patients with peripheral oligoarthritis (7/16 patients; 44%) and axial PsA (5/12; 42%) than with peripheral polyarthritis (3/26, 11%) achieved clinical remission among those with an every-other-week regimen (P <.001).
There were no statistically significant differences in the incidence of adverse events (AEs) between the group of patients receiving biweekly ETN therapy and every-other-week ETN therapy. Baseline characteristics associated with a major clinical response to ETN were shorter disease duration, higher levels of C-reactive protein, and a higher Bath Ankylosing Spondylitis Disease Activity Index. However, none of these parameters reached statistical significance.
Etanercept dosage reduction was not associated with a reduction in AEs in the study, but the investigators said further investigation of longer duration is needed to confirm this finding. They noted that their study was limited by its open-label design, small sample size, and short duration of study.
The researchers conclude that it is possible to increase the ETN dosing interval in patients with remitting PsA initially treated with standard doses--especially patients with axial PsA or peripheral joint oligoarthritis and moderate cutaneous manifestations. “It seems natural that a progressive dose reduction of biological agents should play a crucial role in the therapeutic strategy of PsA,” they note. “Our results are in [agreement with] clinical practice commonly used in many rheumatology services.”
Reference
De Stefano R, Frati E, De Quattro D, de Stefano L. Low doses of etanercept can be effective to maintain remission in psoriatic arthritis patients. J Clin Rheumatol. 2018;24:127-131.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarized the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.